Artificial Heart Program, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, USA.
J Heart Lung Transplant. 2010 Sep;29(9):981-8. doi: 10.1016/j.healun.2010.04.014. Epub 2010 Jul 1.
Ventricular assist devices (VADs) provide effective treatment for end-stage heart failure; however, most patients experience > or =1 major adverse events (AEs) while on VAD support. Although early, non-fatal AEs may increase the risk of later death during VAD support, this relationship has not been established. Therefore, we sought to determine the impact on 1-year mortality of AEs occurring during the first 60 days of VAD support.
A retrospective analysis was performed using prospectively collected data from a single-site database for patients aged > or =18 years receiving left ventricular or biventricular support during 1996 to 2008 and who survived >60 days on VAD support. Fourteen major classes of AEs occurring during this 60-day period were examined. One-year survival rates of patients with and without each major AE were compared.
The study included 163 patients (80% men; mean age, 49.5 years), of whom 87% were European American, 72% had left ventricular support, and 83% were bridge to transplant. The occurrence of renal failure, respiratory failure, bleeding events, and reoperations during the first 60 days after implantation significantly increased the risk of 1-year mortality. After controlling for gender, age, VAD type, and intention to treat, renal failure was the only major AE significantly associated with later mortality (hazard ratio, 2.96; p = .023).
Specific AEs, including renal failure, respiratory and bleeding events, and reoperations, significantly decrease longer-term survival. Renal failure conferred a 3-fold increased risk of 1-year mortality. Peri-operative management should focus on strategies to mitigate risk for renal failure in order to maximize later outcomes.
心室辅助装置(VAD)为终末期心力衰竭患者提供了有效的治疗方法;然而,大多数患者在接受 VAD 支持时会经历 > 或 =1 次重大不良事件(AE)。尽管早期的非致命性 AE 可能会增加 VAD 支持期间后期死亡的风险,但这种关系尚未确定。因此,我们试图确定 VAD 支持的前 60 天内发生的 AE 对 1 年死亡率的影响。
使用来自单个站点数据库的前瞻性收集的数据进行回顾性分析,该数据库用于 1996 年至 2008 年间接受左心室或双心室支持且 VAD 支持 > 60 天的年龄 > 或 =18 岁的患者。检查了在此 60 天期间发生的 14 种主要 AE 类别。比较了有和没有每种主要 AE 的患者的 1 年生存率。
该研究包括 163 名患者(80%为男性;平均年龄 49.5 岁),其中 87%为欧洲裔美国人,72%为左心室支持,83%为桥接移植。植入后前 60 天内发生肾衰竭、呼吸衰竭、出血事件和再次手术显著增加了 1 年死亡率的风险。在控制了性别、年龄、VAD 类型和意向治疗后,肾衰竭是唯一与晚期死亡率显著相关的主要 AE(危险比,2.96;p =.023)。
特定的 AE,包括肾衰竭、呼吸和出血事件以及再次手术,显著降低了长期生存率。肾衰竭使 1 年死亡率增加了 3 倍。围手术期管理应侧重于制定策略来降低肾衰竭的风险,以最大限度地提高后期结果。